Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,578.00
(
1.27%
)
Dow Jones
45,577.47
(
0.00%
)
Brent Oil
100.76
(
-6.82%
)
Bitcoin
70,334.55
(
3.68%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

north40000

Send PM Follow Ignore
Followers 269
Posts 18887
Boards Moderated 0
Alias Born 01/19/2006

north40000

Member Level

Re: willyw post# 190198

Monday, 04/20/2015 4:32:23 PM

Monday, April 20, 2015 4:32:23 PM

Post# of 257269
Investors in GILD should be encouraged by its entry into oncology. I saw its booth at AACL 2015, and its 16-18 page handouts regarding approval of ZYDELIG for treatment of FL and SLL[albeit with boxed safety warning] and potential, off-label indication in CLL for relapsed patients treated with rituximab.[same boxed safety warning] There is additional pipeline.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today